What is PPCB's market cap?

$1.76M, based on the Nov 4 close of $1.79.

Does Propanc Biopharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PPCB is sold short?

50.5K shares, 0.7% of float, as of Oct 15, 2026.

What sector is PPCB in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · PPCBHealthcarePharmaceuticals

Propanc Biopharma, Inc. Common Stock (PPCB)

$1.79+4.68%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.79▼ 99.32% in range

Nov 4, 2025Low $1.71 · High $425.00Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Propanc Biopharma closed at $1.79 on Nov 4, up 4.68%, 99.6% below its 52-week closing high. Volume of 16.6K shares was 0.06× its 20-day average (below normal).

Split-adjusted performance: -63.6% over one month, -92.9% over six months, -99.4% over one year.

Short interest was 50.5K shares at the Oct 15 settlement, down 29.1% from the prior report (0.7% of float, 1.0 days to cover).

Market cap$1.8M983.1K shares

Revenue · quarter$0.00—

Diluted EPS$-17.79—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.71 – 425.00−99.6% from high

Volume16.6K0.06× 20-day avg

Volatility · 60d730.0%Annualised

Short % of float0.7%1.0 days to cover

Net cash$832.0KCash $832.0K

Next earnings—Not scheduled

Split-adjusted performance

1W −15.2%1M −63.6%3M −86.8%6M −92.9%YTD −98.7%1Y −99.4%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum1

Revenue growth—

Net margin—

Value (low P/E)—

Size3

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short50.5K−29.1% vs prior

Days to cover1.0Settled Oct 15

% of float0.7%

Short vol. 10d46.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PPCBPropanc Biopharma	$1.79	+4.68%	−92.9%	—	—	—	$1.8M
GNPXGenprex	$2.14	−7.36%	−89.1%	—	—	—	$1.8M	Compare
OGENOragenics	$0.3720	+0.51%	−40.0%	—	—	—	$1.7M	Compare
KAPAKairos Pharma	$0.4897	−3.03%	−87.4%	—	—	—	$1.7M	Compare
KPTIKaryopharm Therapeutics	$0.0729	−17.44%	−99.2%	−11.9%	−200.5%	—	$1.7M	Compare
SBFMSunshine Biopharma	$2.65	−3.28%	−98.8%	−1.6%	−16.9%	—	$2.0M	Compare
ELABPMGC Holdings	$1.92	−1.03%	−91.0%	—	−225.1%	—	$1.6M	Compare
GOVXGeoVax Labs, Inc. New	$0.1680	+2.38%	−89.8%	−100.0%	—	—	$1.5M	Compare
ERNAErnexa Therapeutics	$1.99	−1.49%	−67.1%	—	—	—	$2.3M	Compare

News about Propanc Biopharma

All news →

No recent articles focused on Propanc Biopharma.

Quick answers

What does Propanc Biopharma do?: Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer.
What is PPCB's market cap?: $1.76M, based on the Nov 4 close of $1.79.
Does Propanc Biopharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PPCB is sold short?: 50.5K shares, 0.7% of float, as of Oct 15, 2026.
What sector is PPCB in?: Healthcare, in the Pharmaceuticals industry.

About Propanc Biopharma

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

HQ: Camberwell, Victoria, C32 employeesListed Jun 15, 2012propanc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology